Bharat Biotech announces ramp up in Covaxin manufacturing capacity, to produce additional 200 million doses
The additional doses would be produced at Bharat Biotech’s subsidiary unit based in Gujarat’s Ankleshwar. The ramping up of manufacturing capacity would effectively scale up the annual production to an estimated one billion doses, the company said.
Vaccine maker Bharat Biotech Limited on May 20 announced a ramp up of the manufacturing capacity for its COVID-19 vaccine, Covaxin, with 200 million additional doses to be produced at its subsidiary unit based in Gujarat.
The statement issued by the company claimed that the production capacity has been increased at Chiron Behring Vaccines, a wholly-owned subsidiary of Bharat Biotech located in Gujarat’s Ankleshwar.
“The company plans to produce 200 million doses of Covaxin per annum in the GMP facilities that are already operational for the production of vaccines based on inactivated vero cell platform technology,” it added.
The production availability at the Ankleshwar-based manufacturing plant will commence from fourth quarter of 2021, Bharat Biotech claimed.
COVID-19 vaccines | Bharat Biotech to increase production of Covaxin to 10 crore doses by October: MoS Home
With this, the overall production of Covaxin — Bharat Biotech’s COVID-19 vaccine — will increase to 10 crore in June, 17 crore in July, 19 crore in August and 40 crore in September, added the ministry.
The Union Ministry of State for Home on May 20 announced that Hyderabad based Bharat Biotech will increase the production of Covaxin from the present 1.7 crore doses per month to 10 crore doses by October.
With this, the overall production of Covaxin — Bharat Biotech’s COVID-19 vaccine — will increase to 10 crore in June, 17 crore in July, 19 crore in August and 40 crore in September, added the ministry. Till now the pharma firm had produced a total of 4.12 crore Covaxin shots so far, which includes both the doses.
Bharat Biotech Limited announced a ramp up of the manufacturing capacity for its COVID-19 vaccine, Covaxin, with 200 million additional doses to be produced at its subsidiary unit based in Gujarat.
